Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria

References

• Socie G, Rosenfeld S, Frickhofen N, et al. Late clonal diseases of treated aplastic anemia. Semin Hematol. 2000;37(1):91–101.
   PubMed Web of Science ®Google Scholar
• Babushok DV, Perdigones N, Perin JC, et al. Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia. Cancer Genet. 2015;208(4):115–128.
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Jiang J, Smith AE, et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood. 2014;124(17):2698–2704.
   PubMed Web of Science ®Google Scholar
• Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med. 2015;373(1):35–47.
   PubMed Web of Science ®Google Scholar
• Lane AA, Odejide O, Kopp N, et al. Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia. Leukemia. 2013;27(4):968–971.
   PubMed Web of Science ®Google Scholar
• Heuser M, Schlarmann C, Dobbernack V, et al. Genetic characterization of acquired aplastic anemia by targeted sequencing. Haematologica. 2014;99(9):e165–167.
   PubMed Web of Science ®Google Scholar
• Huang J, Ge M, Lu S, et al. Mutations of ASXL1 and TET2 in aplastic anemia. Haematologica. 2015;100(5):e172–175.
   PubMed Web of Science ®Google Scholar
• Ray JG, Burows RF, Ginsberg JS, et al. Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and recommendations for management of the pregnant and nonpregnant patient. Pathophysiol Haemos Thromb. 2000;30:103–117.
   Google Scholar
• Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121(25):4985–4996.
   PubMed Web of Science ®Google Scholar
• Alexion Pharmaceuticals Inc. Soliris (eculizumab) [package insert]; 2018. http://alexion.com/Documents/Soliris_USPI.aspx.
   Google Scholar
• CDC. Meningococcal ACIP recommendations: US Department of Health and Human Services. CDC; 2017.
   Google Scholar
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125166s172lbl.pdf.
   Google Scholar
• Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233–1243.
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133(6):540–549.
   PubMed Web of Science ®Google Scholar
• Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530–539.
   PubMed Web of Science ®Google Scholar
• Shen W, Clemente MJ, Hosono N, et al. Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria. J Clin Invest. 2014;124(10):4529–4538.
   PubMed Web of Science ®Google Scholar
• Mortazavi Y, Tooze JA, Gordon-Smith EC, et al. N-RAS gene mutation in patients with aplastic anemia and aplastic anemia/paroxysmal nocturnal hemoglobinuria during evolution to clonal disease. Blood. 2000;95(2):646–650.
   PubMed Web of Science ®Google Scholar
• Sugimori C, Padron E, Caceres G, et al. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. Blood Cancer J. 2012;2(3):e63–e63.
   PubMedGoogle Scholar
• Cilloni D, Messa F, Arruga F, et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica. 2008;93(6):921–924.
   PubMed Web of Science ®Google Scholar
• Lapillonne H, Renneville A, Auvrignon A, et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol. 2006;24(10):1507–1515.
   PubMed Web of Science ®Google Scholar
• Weisser M, Kern W, Rauhut S, et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia. 2005;19(8):1416–1423.
   PubMed Web of Science ®Google Scholar
• Bader P, Niemeyer C, Weber G, et al. WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia? Eur J Haematol. 2004;73(1):25–28.
   PubMed Web of Science ®Google Scholar
• Minetto P, Guolo F, Clavio M, et al. Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes. Leuk Res. 2015;39(8):866–873.
   PubMed Web of Science ®Google Scholar
• Ogata K. WT1 expression in patients with myelodysplastic syndromes: a variety of possibilities in future clinical practice. Acta Haematol. 2017;137(1):30–31.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Liu L, Wang J, et al. The Wilms' tumor gene-1 is a prognostic factor in myelodysplastic syndrome: a meta analysis. Oncotarget. 2018;9(22):16205–16212.
   PubMedGoogle Scholar
• Falini B, Martelli MP, Bolli N, et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood. 2011;117(4):1109–1120.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221.
   PubMed Web of Science ®Google Scholar
• Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, et al. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv. 2019;3(6):922–933.
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111–121.
   PubMed Web of Science ®Google Scholar
• Desai P, Mencia-Trinchant N, Savenkov O, et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med. 2018;24(7):1015–1023.
   PubMed Web of Science ®Google Scholar